3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
22
Terminated
8
Unknown
3
Recruiting
3
Withdrawn
1
Active not recruiting
1
Sponsor Class
OTHER
3
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Thoracic
4
Tumor-Agnostic
3
Plasma cell
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Neoplasms
2
Neoplasm Metastasis
1
Interventions
pembrolizumab
25
Specimen Handling
17
Blood Specimen Collection
17
Biopsy
16
Magnetic Resonance Spectroscopy
15
atezolizumab
11
Surveys and Questionnaires
11
Bevacizumab
9
Radiotherapy
8
Radiosurgery
8
Nivolumab
8
Fluorouracil
8
Standard of Care
7
Paclitaxel
7
Irinotecan
7
Gemcitabine
7
Cisplatin
7
olaparib
6
durvalumab
6
Palliative Care
6
Oxaliplatin
6
Leucovorin
6
Cyclophosphamide
6
Carboplatin
6
Capecitabine
6
alectinib
5
abemaciclib
5
Trastuzumab
5
Interviews as Topic
5
Exercise
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Erlotinib Hydrochloride
×
Tumor-Agnostic
×
Clear all
NCT04341181
2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2
Recruiting
300 enrolled
NCT05525858
2025-04-27
KOSMOSII
Seoul National University Bundang Hospital
Recruiting
1,000 enrolled
NCT02925234
2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2
Recruiting
1,550 enrolled